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Abstract
Alterations of the volatile metabolome (the collection of volatiles present in secretions and
other emanations) that occur in response to inflammation can be detected by conspecifics and
chemometric analyses. Using a model system where mouse urinary metabolites are altered by
treatment with lipopolysaccharide (found in the outer cell membrane of gram-negative bacteria),
we hypothesized that alteration of body odor volatiles will vary according to the pathogen responsible for inducing the inflammation. We tested this hypothesis by treating mice with different
immunogens that engage different immune signaling pathways. Results suggest that alterations
of body odor volatiles resulting from inflammation do contain detailed information about the type
of pathogen that instigated the inflammation and these differences are not merely dependent on
the severity of the inflammatory event. These results are encouraging for the future of differential
medical diagnosis of febrile diseases by analysis of the volatile metabolome. In particular, our data
support the possibility that bacterial infections can be differentiated from viral infections such that
antibiotic drug stewardship could be drastically improved by reducing unneeded treatments with
antibiotics.
Key words: antibiotic resistance, bodily odors, febrile diseases, infection, inflammation, volatile metabolome

Introduction
It is well established that bodily odor volatiles (those metabolites
originating from urine, glandular secretions, and other sources observed in the vapor phase and detectable by olfaction) is the primary source of social communication for many species (Brennan and
Kendrick 2006; Johnston 2003; Kelliher 2007). Behavioral studies
have indicated that members of the same species may use these volatile signals to regulate social interactions (e.g., attraction, affiliation,
and avoidance). It is also established that these body odors may be
influenced by variation in physiological status induced by inflammation, infection, and disease. For example, members of the opposite
sex discriminate between odors of sick and healthy individuals, and

several studies suggest that female mice are more attracted to the
odors of healthy compared to sick males and may actively avoid
odors of infected males (Kavaliers et al. 2005).
Similarly, multiple studies have demonstrated that human patients with pathological conditions such as cancer (Bernabei et al.
2008; Bajtarevic et al. 2009; Jezierski et al. 2015), intestinal infection (Burdette and Bernstein 2007), diabetes (Greiter et al. 2010),
tuberculosis (Mgode et al. 2012; Mahoney et al. 2013), and other
conditions (Bijland et al. 2013) exhibit alterations of body odor.
As such, there has been significant interest in recent years in developing chemometric approaches using techniques such as gas chromatography/mass spectrometry, in addition to employing animal
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biosensors, to diagnose illnesses. These chemometric studies rarely
reveal the presence of novel volatile metabolites in patient samples
(Amann et al. 2014; Kimball 2016), with the notable exception of
exhaled breath during pulmonary infection (Phillips et al. 2012; van
Oort et al. 2018). Instead, illness regularly results in alteration of the
pattern of volatile metabolites present in the healthy state. The origin
of these alterations is currently unknown. Furthermore, the specificity of these volatile patterns with respect to individual illnesses
has not yet been established. In fact, little is known about the
mechanism(s) responsible for alterations of the volatile metabolome.
In rodents, inflammation induced by lipopolysaccharide (LPS,
the cell wall material of gram-negative bacteria) impacts the body
odor volatile profile (Arakawa et al. 2010; Arakawa et al. 2011a,
2011b; Kimball et al. 2014; Gervasi et al. 2018; Millet et al. 2018).
LPS is frequently used in models of inflammation, owing to its ability
to produce a robust immune response (Beeson 1947; Geppert et al.
1994; Baldwin 1996; Raetz and Whitfield 2002; Lu et al. 2008).
In addition to LPS treatments, we found that treatment with inflammatory cytokines also alters body odor profiles (Millet et al.
2018). Functionally, the changes in body odor induced by LPS can
cause healthy conspecifics to avoid the odor of the sick individual
(Arakawa et al. 2009a, 2009b).
How inflammation leads to the alteration of body odors is
not understood. However, membrane-spanning Toll-like receptors
(TLRs) that recognize pathogens according to each microbe’s conserved molecular pattern motif are likely involved. For example,
TLR4 recognizes gram-negative bacteria by their common LPS
exterior. While innate immune responses mediated by TLRs lack
the versatility of the adaptive immune response, they can quickly
respond to an array of common pathogenic molecules. Upon recognizing their ligand, TLRs rapidly promote the cellular immune
response resulting in hallmarks of inflammation, including the release of chemokines and cytokines via one or both of 2 signaling
cascades (Figure 1). TLR4 is unique among the Toll-like receptors
in that it activates inflammation through both MyD88-dependent

Figure 1. Upon recognizing their ligand, Toll-like receptors (TLRs) rapidly promote inflammation and release of chemokines and cytokines [figure adapted
from Lu (2008)]. TLR4 uniquely activates inflammation through both MyD88dependent (blue) and MyD88-independent (red) pathways. Both pathways
activate the master regulators of inflammation, NF-kB and MAPK (purple).
Other TLRs activate only one of these 2 pathways. MyD88 (blue) also activates IRF5, which helps activate pro-inflammatory cytokines. TRIF (red) produces an immune response directed toward the production of interferons.
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and MyD88-independent pathways (Lu et al. 2008). Other TLRs activate only one of these 2 pathways. For example, MyD88 activates
IRF5, which helps activate pro-inflammatory cytokines such as TNF,
IL-6, and IL-12 (Takeda and Akira 2004; Takaoka et al. 2005). The
MyD88-independent pathway, mediated by TRIF, produces an immune response directed more toward the production of interferons
(Takeda and Akira 2004; Hacker et al. 2006; Choi et al. 2011).
As indicated, we and others have demonstrated that LPS alters body odor (Arakawa et al. 2010; Kimball et al. 2014; Gervasi
et al. 2018; Millet et al. 2018). In this and previous studies, we
used urine as a representative source of body odor. Urine is considered “a window into the body” and has been demonstrated to be
a major source of overall murine body odor (Schaefer et al. 2001;
Yamazaki et al. 2002). We hypothesized that distinctive body odor
volatile profiles, as observed in urine, would also result from differential TLR recognition and/or stimulation of the MyD88 and TRIF
intermediate pathways (Figure 1). To test this, we engaged different
immune pathways by treating mice with several molecules known to
differentially activate cellular immunity via interaction with specific
TLRs. Collectively, these molecules (which, like LPS, are not pathogenic themselves) are among those molecules known as pathogenassociated molecular patterns (PAMPs). In addition to LPS, which
activates both MyD88 and TRIF via recognition by TLR4 (responsible for recognition of gram-negative bacteria), we employed
2 PAMPs that individually activate only one of the intermediate
pathways (Figure 1). One, the synthetic lipopeptide Pam3CSK4,
activates MyD88 (Aliprantis et al. 1999; Brightbill et al. 1999) by
way of the TLR2/TLR1 heterodimer (responsible for recognition
of gram-positive bacteria). The other, synthetic double-stranded
RNA poly(I:C), is a ligand for TLR3 (responsible for recognition
of double-stranded viral RNA) and activates TRIF (Alexopoulou
et al. 2001). We chose these 2 molecules to determine whether viral
and bacterial PAMPs may produce different odorant patterns. If this
were the case, it might be possible to design diagnostic volatile analysis platforms to differentiate broad classes of infections.
To test this, we used 2 complementary approaches. First, we
trained biosensor animals in a Y-maze to discriminate odor produced by mice injected with a high dose of LPS compared to mice
given a vehicle injection (control). The mice were then tasked to
apply this learning to the presentation of novel odors resulting from
treatment with other PAMPs or lower dose LPS in unrewarded blind
generalization trials. These behavioral tests served important purposes. Specifically, we reasoned that if the mice were unable to discriminate by olfaction between LPS-treated mice and mice treated
with other PAMPs then it would be highly unlikely that differences
could be discerned by gas chromatographic analyses. Consequently,
successful behavioral tests justified our going forward with the
chemometric work. Successful behavioral tests also would motivate
future studies on the communicatory function of different inflammatory pathways.
After the successful behavioral assays, we “trained” a
chemometric model to discriminate between the patterns of volatiles produced by treatment with either the 3 PAMPs (LPS,
Poly(I:C), and Pam 3CSK4) and controls. Evidence in support of
our hypothesis that different pathogens would promote differing
and recognizable patterns of volatile metabolites would contribute
an important step toward the goal of exploiting the volatile metabolome as a tool for diagnosing febrile (having symptoms of a fever)
diseases. In particular, we wish to determine if it might be possible
to differentiate bacterial compared to a viral infection which could
be used clinically to inform proper use of antibiotic drugs in humans and other animals.
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Materials and methods
Subjects
Inbred male C57BL/6J mice were bred in our laboratory (trained
biosensors) or purchased from Jackson Laboratories (urine donor
subjects). The donor mice were treated as described below for urine
and blood donation at 6–10 weeks old. Donors had ad libitum access to food and water before and after treatment. Biosensor mice
began training at 5 weeks of age. Biosensors had ad libitum access
to food but were restricted from water 23 h a day during behavioral
experiments that employed water as a reward. Biosensors received
water during and after every behavioral experiment (having 1 h to
satiate). Because lack of adequate access to water will lead to significant loss of body condition, the body mass of biosensor mice was
monitored. Animal procedures described here were approved by the
Monell Internal Animal Care and Use Committee (protocols #1174
and #1183) and compliant with the animal care and use regulations
promulgated in 9 CFR parts 1, 2, and 3.

Treatments
To obtain urine samples for bioassay training, 20 mice were injected
(0.2 mL i.p.) with 250 μg/mL LPS in 0.01M phosphate-buffered saline (PBS) solution (high dose = 2.0 mg/kg) or PBS solution only.
For critical generalization trials, 10 (each) mice were given 0.2 mL
i.p. injections of either 6.25 μg/mL LPS (low dose = 0.05 mg/kg),
250 μg/mL Poly(I:C) (2 mg/kg), or 250 μg/mL Pam3CSK4 (2 mg/kg)
prepared in 0.01M PBS solution.

Inflammation monitoring
Blood was collected from a subset (15) of donor mice at 2 h
post-treatment under 2% isoflurane anesthesia via tail vein in
microcentrifuge tubes containing 3.8% w/v sodium citrate solution.
Blood was immediately centrifuged and plasma removed. Plasma
was stored at −40 °C until use for enzyme-linked immunosorbent
assays (ELISA) for TNF and IL-1β using Quantikine ELISA kits as
directed by the manufacturer (R&D Systems, Minneapolis, MN).
Body mass data were also collected from these subjects and all data
were analyzed by ANOVA to determine if parameters were impacted
by treatment.

Urine collection
Urine was collected daily from mice by application of gentle abdominal pressure, as described elsewhere (Yamazaki et al. 1983; Millet
et al. 2018). Once collected, urine was immediately stored at −20 °C
pending behavioral or chemometric analysis. Urine was collected
daily from days 4 to 28 days following treatment. Urine samples
were not collected before day 4 so that any effects of fasting (food
intake declines for about 48 h following treatment with LPS for example) and anesthesia (isoflurane used for blood collection) were
minimized in the odor profile of the urine samples.

Behavioral assay
Odor discrimination tasks by a panel of 6 trained biosensors were
conducted using a Y-maze apparatus, in which mice are presented
with a choice of 2 urine odors. The odor training and generalization steps were described previously (Yamazaki et al. 2002). Briefly,
the air was conducted through 2 odor chambers, containing urine
(0.5 mL) exposed in 35 mm Petri dishes (11 mL) to the 2 arms of the
maze. To attain necessary volumes for bioassay (particularly for rewarded training trials), urines collected from the same individual on
multiple collection days were often combined. Samples representing
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different donors from specific treatments were randomly assigned
to the left or right odor boxes of the Y-maze for each trial. Gates
were manually raised and lowered in a timed sequence to permit the
training or testing of each mouse in training sessions generally consisting of 35–50 two-choice trials. During training, biosensors were
given a water reward (approx. 10 μL) for going to the arm of the
Y-maze scented by urine odor from LPS (2 mg/kg)-treated donors
(4–28 days post injection) when the other arm was scented by urine
odors of PBS-treated donors (1–28 days post injection).
Testing of novel stimuli (urine stimuli collected from mice never
before encountered by the trained mice) in the Y-maze relies on the
tendency of trained biosensors to seek the learned odor-associated
with reward. That is, trained biosensors will choose the maze arm
scented with novel stimuli that perceptually resemble the training
stimuli. This is achieved by training biosensors to associate odor
A with a reward when presented opposite of odor B in the Y-maze.
Following training, subsequent unrewarded comparisons between a
novel odor and odor B yield information regarding relationships between the novel odor and the training odor (odor A).
Mice were trained to associate a reward with a selection of urine
odor from LPS-treated mice (odor A) when presented in comparison
with urine odor from PBS-treated mice (odor B). Training consisted
of reinforcing the selection of the arm of the maze scented by LPS
odor by providing thirsty mice with a drop of water upon correct
selection. When they reliably (greater than 80% of the trials) chose
the arm scented by LPS odor, validation and generalization trials
with novel stimuli commenced. Each session began with a series of
rewarded trials using training stimuli. Generalization trials were initiated after 6 consecutive (or 8 of 9) correct rewarded trials. If the
mouse did not achieve the required performance in rewarded trials,
the session was terminated and re-established the next day. Trained
mice were never reinforced with water in generalization trials regardless of Y-maze arm selection.
The first generalization trials, termed validation trials, were designed to determine whether the mice learned to differentiate treatment with LPS from treatment with PBS—as opposed to learning
about individual identities of urine donors. This is a necessary
evaluation even though the donor mice are inbred and hence assumed to be genetically identical. Upon correct selection of odors of
novel LPS-treated mice, we can conclude that the mice have learned
that LPS treatment produces urine odor that is different than that
produced by PBS treatment. Validation trials were conducted with
urines collected from novel LPS (2 mg/kg) and PBS-treated donors.
Following evidence from validation trials that trained biosensors were selecting the maze arm containing LPS-derived odor in
favor of PBS-derived odors, generalization trials were conducted
to test the hypothesis that activation of cellular immunity induces
distinctive changes in mouse volatile profiles according to the
TLR-initiated pathway. Just as urine odor associated with LPS
treatment (odor A) was presented in the Y-maze versus urine odor
associated with PBS treatment (odor B), test odors were always
presented versus odor B in generalization trials. In this way, we
tested the extent to which treatment with Poly(I:C), Pam3CSK4,
or low-dose LPS produces urine odors perceived as similar to
odors elicited by treatment with LPS (odor A). Owing to generalization behavior, if trained mice perceived Poly(I:C) odor to be
similar to LPS odor we would expect the trained mice to select the
arm of the Y-maze scented with urine from Poly(I:C)-treated mice
in search of the LPS odor-associated reward. This same prediction would hold for other test odors (i.e., urine from Pam3CSK4
or low-dose LPS-treated mice). Conversely, if the test odor is not
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perceptively similar to the learned LPS odor, we would not expect
the trained mice to select the Y-maze arm scented with the test
odor in search of the water reward. Trials with urines collected
from mice treated with Poly(I:C) or Pam3CSK4 were interspersed
in the same testing sessions. These were followed by additional
sessions employing trials with urines collected from mice treated
with low-dose LPS.

Behavioral data analysis
For each set of generalization trials, responses coded as “correct”
(selection of the PBS urine odor B was coded as “incorrect”) were
divided by the total (correct plus incorrect) number of trials. These
data from all biosensors were combined. Each data set representing a
unique generalization experiment contained n ≥ 75 total trials. Data
were then subject to 2-tailed binomial proportion hypothesis testing
using the PROC FREQ function of SAS Studio. Significance was determined by the exact test of binomial proportion. An analysis of
variance (ANOVA) was also conducted to determine if all biosensor
mice in this study responded similarly to the treatment urines and
if responses differed according to treatment using ratios as the response and trained mouse ID and treatment as fixed effects.

Headspace GC/MS
Following completion of behavioral sessions, 92 available urine samples representing 4 LPS, 7 control, 5 Poly(I:C), and 8 Pam3CSK4
donors were subjected to volatile analyses. Twenty-five μL samples
of urine were placed in 20-mL headspace vials and fortified with
10 μL of an internal standard consisting of 10 μg/mL L-carvone in
water (such that 100 ng was delivered to each sample). At least 3
urine samples (collected 4–28 days post-treatment) from each subject were analyzed by headspace gas chromatography/mass spectrometry (GC/MS). Quality control samples consisting of empty
vials or vials containing only 100 ng of L-carvone were also analyzed throughout each chromatographic run (usually consisting of
24 urine samples). Quality control samples were used to monitor
chromatographic system suitability and assist in the exclusion of
chromatographic peaks not related to urine. Samples were analyzed
using a HT3 dynamic headspace analyzer (Teledyne Tekmar) with a
Supelco Trap K Vocarb 3000 thermal desorb trap (Sigma-Aldrich)
attached to a Trace Ultra gas chromatograph (Thermo Scientific)
equipped with a single quadrupole mass spectrometer (ISQ, Thermo
Scientific). Samples were incubated at 40 °C and swept with helium
for 10 min at 75 mL/min as volatile metabolites were collected on
the thermal trap. After collection of volatiles, the trap was heated to
260 °C and volatiles were desorbed directly onto the gas chromatograph equipped with 30 m × 0.25 μm Stabilwax-DA (Restek) capillary column. Split injections (5:1) were made with a column flow
of 2.0 mL/min and a split vent flow of 10.0 mL/min. The GC oven
began at 40°C (3 min) and ramped to 260 °C at a rate of 7 °C/min.
The mass spectrometer was operated in scan mode from 33–400
m/z. Tentative chromatographic peak identifications were based on
the NIST Standard Reference Database.

Data were subjected to principal components analysis (PCA) using
Unscrambler (CAMO Software; Oslo, Norway) to visually identify
outliers exhibiting undue influence or leverage in residual plots.
Subject means (from analysis of multiple samples from the
same donor) were calculated and subjected to stepwise linear discriminant analysis (LDA) model building using PROC STEPDISC
in SAS. Contingency tables for treatment classifications were constructed using PROC DISCRIM with cross-validation to determine
the overall validity and error rate of the model. Mean carvonestandardized peak responses of predictors identified by the model
building were calculated for each treatment for graphical presentation of the volatile patterns associated with each PAMP.

Results
Treatments induced inflammation
Mice displayed evidence of illness for 24–72 h following treatment
with each PAMP. Effects included lethargy, reduced grooming, and
anorexia. Mice treated with a high dose of LPS lost the most body
mass in the early days following treatment (Figure 2A). The inflammatory cytokines produced in response to treatment with Poly(I:C),
Pam3CSK4, or low-dose LPS were lower than counterparts receiving
the 2.0 mg/kg LPS high dose (Figure 2B). Together, these data indicate that while treatment with all 3 PAMPs induced inflammation, the inflammatory response was strongest in the 2.0 mg/kg
LPS-treated mice.

Chemometric analyses
Chromatographic data were exported to MetAlign software for peak
alignment and noise elimination (Lommen 2009). The resulting data
were analyzed by MSClust for mass spectral extraction and assignment of a single peak response value based on the extracted selected
ion monitoring (SIM) trace (Tikunov et al. 2012). Peak responses
were normalized to the L-carvone response from each sample.

Figure 2. (A) Relative change in body mass, normalized to day 0 mass. Letters
indicate differences among changes in body mass according to treatment
and day. (B) TNF and IL-1B responses were found in serum 2 h post-treatment
(as determined by ELISA) relative to responses resulting from treatment with
2.0 mg/kg LPS. Letters indicate differences among responses. All relative responses were significantly less than 100% (P < 0.0001 except for the value
indicated with “a,” P = 0.0141).
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Behavioral assays

Chemometric model

Biosensors correctly recognized the urine odors of novel mice
(mice whose urine odors of LPS or PBS were never previously experienced) 73% of the time in validation trials which indicated that
the training was not specific to the individual urine donors used
during training (Figure 3; black bar). That is, the mice learned the
urine odor differences between treatment with LPS-induced inflammation and control (PBS), not the unique individual odors of
the donor mice. In contrast, mice did not generalize this learning
to urine odors associated with inflammation caused by treatment
with Poly(I:C) or Pam3CSK4 (Figure 3; middle bars). Biosensors
generalized to Pam3CSK4-urine odor only 31% of the time, and
to Poly(I:C) urine odor only 34% of the time. Both of these identification rates were significantly lower than that expected by
chance (P = 0.00061 and P = 0.0026, respectively). This indicates
that biosensors perceived the urine odor of both these treatments
to be different than LPS-induced urine odor.
Generalization trials with low-dose LPS were used to test
whether simple variations in the severity of inflammation might be
coded differently. Mice generalized to low-dose LPS 65% of the time
(P = 0.0080), indicating that these urines smelled very similar to the
training odor (Figure 3; right bar). ANOVA results indicated that responses did not differ among the trained biosensors (P = 0.624) and
confirmed that responses differed among treatments (P = 0.0009).
Specifically, responses did not differ between validation and lowdose trials (P = 0.4124), nor did responses differ between Poly(I:C)
and Pam3CSK4 (P = 0.9563). However, the responses to these
PAMPs were lower than both validation trials with 2.0 mg/kg LPS
validation trials and low-dose (0.05 mg/KG) LPS trials (Figure 3).
Trained mice demonstrated that LPS urine odor is perceptively
different from both Poly(I:C) and Pam3CSK4. However, these
behavioral trials cannot determine whether Poly(I:C) and Pam3CSK4
are different from each other. Generalization of the learned response
also shows that high- and low-dose LPS odor share odor characteristics. However, we cannot conclude that they would not be discriminated if other test procedures were employed.

Peak response data from 9 (of 92) samples were determined to be
outliers and one sample analysis was incomplete (no visible peaks
in the chromatogram). Forty-nine peaks (not including the carvone
internal standard) were determined to be of sample origin as they
did not occur in the quality control samples. All tentatively identified urine volatiles were previously reported in mouse urine (Willse
et al. 2005; Kwak et al. 2008). The LDA model yielded a 5-peak
model capable of discriminating among LPS, Poly(I:C), Pam3CSK4,
and control treatments (Table 1). The model had an average squared
canonical correlation of 0.600 and a cross-validation error rate of
21.5%, indicating that samples were classified to the correct treatment 78.5% in out of sample testing. Predictors were tentatively
identified as o-toluidine, 5-hepten-2-one, 6-methyl-3-heptanone,
2-ethyl-1-hexanol, and dimethylsulfone (Figure 4).

Figure 3. Mean responses of biosensors in the Y-maze apparatus in unrewarded, blind generalization trials (with 95% confidence intervals). All biosensors were trained to select the arm of the Y-maze scented by urine odors
of mice treated with high-dose (2.0 mg/kg) LPS in a 2-choice paradigm where
the alternative side of the maze is scented by mice given a control PBS
vehicle treatment. Responses differed among treatments (P = 0.0009) and
responses with different letters were significantly different from each other
(α = 0.05).

Discussion
Previous studies demonstrate that various inflammatory stimuli
differ in how they influence the mouse urinary volatile profile
(Kimball et al. 2014; Millet et al. 2018). Toward an explanation
for these observed differences, we used complementary approaches
to test the hypothesis that activation of different cellular immune
response pathways results in the production of distinctive urinary
volatile profiles. Owing to the design of 2-choice behavioral assays and the role of generalization in learning and memory, biosensor mice trained to discriminate LPS from PBS (control) odors
would be expected to generalize their positive LPS odor response to
similar odors.
Behavioral assay results (Figure 3) suggest that the patterns of
volatiles produced by LPS and Poly(I:C) and by LPS and Pam3CSK4
were perceptually distinct. Since Poly(I:C) and Pam3CSK4 were not
tested against each other we cannot infer whether these share similar
or dissimilar odor percepts. It is noteworthy that responses to these
latter 2 PAMPs favored going to the arm of the maze scented by
the control (PBS) odor compared to the odor of the treated mice.
This may suggest that odors of Poly(I:C) and Pam3CSK4 were so
different than odor induced by LPS that the trained mice chose the
control odor because it was familiar (even if PBS odor had never
been reinforced). Further studies on responses of untrained mice
could shed light on this result. In any case, we conclude that activation of these 2 pathways produced urinary odors that were very
different than those produced by LPS activation. Based on generalization results associated with the odor of the low-dose LPS, we can
also conclude that differences in volatile patterns observed here (and
in previous studies) from the administration of different stimuli are
unlikely due solely to differences in inflammation intensity produced
by the immunogen (Figure 3). However, we cannot completely rule
out that the volatile metabolome may be influenced in some manner
by the intensity of the inflammatory response.
Unlike discriminations made by trained animals in the Y-maze,
chemometric comparisons do not share the maze’s limitation of
binary choice or the need to make inferences based on generalization behavior. Rather, multi-level comparisons are possible. Using
the chromatographic data from treatment with LPS, Pam3CSK4,
Poly(I:C), or PBS, the LDA model demonstrated that patterns of 5
key volatiles differ significantly among the treatments in a manner
that could be used to predict which TLR pathway was initiated
(Table 1 and Figure 4). These same volatiles have been implicated in
previous studies of the volatile metabolome and inflammation. For
example, 2-ethyl-1-hexanol and 6-methyl-3-heptanone were both
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Table 1. The number of urine donors assigned to each treatment by the linear discriminant analysis (LDA) model constructed from the
chromatographic peak responses of 5 odorants (see Figure 4)
To:

LPS (TLR4)

Pam3CSK4 (TLR1/2)

Poly(I:C) (TLR3)

PBS (Control)

4
0
0
0

0
7
0
0

0
0
4
0

0
1
1
7

From:
LPS
Pam3CSK4
Poly(I:C)
PBS

Twenty-two of 24 urine donors were correctly classified according to treatment (TLR responsible for pathogen recognition indicated in parentheses).

Figure 4. Radar plot of mean standardized peak responses the 5 compounds
identified in the linear discriminant analysis model (see Table 1). Peak responses are standardized to the carvone internal standard. Thus, a standardized peak response of 0.5 is 50% of the response observed for carvone
added to that sample. For ease of presentation, standardized peak responses
were increased 5× for 6-methyl-3-heptanone and o-toluidine and 20× for
dimethylsulfone.

identified in previous metabolomic studies of LPS (Gervasi et al.
2018; Millet et al. 2018). Similarly, o-toluidine and dimethylsulfone
were identified in a study of murine traumatic brain injury models
(Kimball et al. 2016). Importantly, we cannot conclude that mice
used these same 5 odorants in the behavioral assays. More generally,
the odorants mediating olfactory discrimination and that volatiles
identified in the chemometric studies may not be the same. Further
work is required to address this issue.
Our results suggest that pathogen recognition by specific TLRs
may dictate the pattern of volatile metabolites and are consistent
with the possibility that bacterial and viral infections result in diagnostically relevant alterations of the volatile metabolome. Just as TLR
recognition of LPS by TLR4, Poly(I:C) by TLR3, and Pam3CSK4 by
TLR1/2 results in unique alterations of the volatiles in this study, it
may also be the case that TLR recognition of gram-negative bacteria by TLR4, viral RNA by TLR3, and gram-positive bacteria by
TLR1/2 would do likewise. However, our results do not yield insight
into how MyD88 and TRIF pathways specifically contribute to alterations of the volatile metabolome resulting from cellular immunity.
One important purpose of studying the mechanisms underlying
the production of distinctive volatile profiles is the light this work
may shed on differential disease diagnosis. Differential diagnoses can
be challenging in certain medical conditions. For example, more rapid
differential diagnosis in sepsis and systemic inflammatory response
syndrome (SIRS) would be of great benefit to patients. Delaying
antimicrobial treatment for septic patients by a matter of hours

significantly increases the risk of mortality (Barie et al. 2005; Morrell
et al. 2005; Kumar et al. 2006). As a result, standard emergency
medical intervention for patients suspected of sepsis is immediate
treatment with broad spectrum antimicrobials, before any microbiological testing confirming the identity or existence of the responsible
pathogens (Angus and van der Poll 2013; Dellinger et al. 2013). Lack
of differential diagnosis in these conditions and others can lead to
unnecessary treatments with antibiotics and antimicrobials not targeted to the specific causative pathogen. This unnecessary treatment
can subject patients to potentially toxic side effects, and contribute
to the rise of treatment-resistant microorganisms.
The differential diagnosis of febrile diseases is specially challenging in low-resource environments (WHO 2018). In particular,
it is often difficult to determine whether there is a bacterial or a
nonbacterial cause for a child who presents with a fever. For example, following the exclusion of malaria as the cause of fever in
areas where malaria is endemic, identifying whether or not febrile illness with fever is caused by a bacterium or virus is a key first step for
guiding treatment. Routine default treatment with antibiotics, “just
to be on the safe side,” is particularly common in low and middleincome countries. In addition to the higher fatality rates from drugresistant infections, children with drug-resistant infections require
more expensive treatments which can have more adverse effects and
excess and prolonged hospitalizations.
Diagnostic tests for febrile diseases have been broadly classified
into pathogen-specific and pathogen nonspecific tests (Bhaskaran
et al. 2019). Pathogen-specific assays have the goal of diagnosing the
specific disease that is causing the presenting fever that may be accompanied by other symptoms such as cough, diarrhea, and general
malaise. In contrast, pathogen nonspecific assays are markers that
only differentiate bacterial from nonbacterial causes of fever. The
vast majority of biomarkers currently being evaluated to discriminate bacterial from nonbacterial causes of acute febrile illness involve hematological factors, inflammatory molecules, cytokines, cell
surface and metabolic markers, and various combinations of these
markers (Dittrich et al. 2016; Kapasi et al. 2016). These biomarkers
are typically collected from blood and plasma. While molecular techniques for both bacteria and viruses hold great promise for specific
disease diagnosis, they too often suffer from high technical barriers
in terms of cost as well as complexity and need for advanced technical support and know-how.
Our results suggest that analysis of urine volatiles could potentially allow rapid differential diagnosis between pathogens, or at
minimum, between certain classifications of pathogens (Figure 5).
This could allow for more targeted treatments in cases where the
differential diagnosis is currently difficult. Based on this present
study, we can conclude there is at least more than one type of inflammatory odor profile. This suggests that many pathogens, or at least

Chemical Senses, 2021, Vol. 46

7

References

Figure 5. Pathogens are recognized by toll-like receptors to initiate a cascade of chemokines, cytokines, and other metabolites. The resulting volatile metabolites may be used to determine the source of the infection.
Lipopolysaccharide (LPS), Pam3CSK4, and Poly(I:C) were used to trigger
cellular immunity through recognition by TLR4, TLR1/2, and TLR 3 (respectively) to promote alterations of urinary volatiles in mice. Mouse behavioral
studies indicate that mice could smell the difference between LPS-induced
odors and odors induced by treatments of each of the other pathogens. The
chemometric model could discriminate from among patterns of volatiles induced by treatments of all 3 of these pathogens.

classes of pathogens, will have distinct body odor volatile profiles.
Our research indicates that analysis of volatile metabolites has the
potential as a differential diagnostic tool. Our data suggest that alteration of body odor as a result of inflammation does not represent
a generalized physiological response that occurs regardless of the
initial source of the inflammation. Instead, different pathogens result
in different volatile metabolite patterns. Future research is needed
to further clarify how dissimilar a pathogen must be for differential
diagnosis from analysis of the volatile metabolome. We believe this
finding is encouraging for the future of volatile metabolomic analysis
as a medical diagnostic tool.
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